𝔖 Bobbio Scriptorium

✦ LIBER ✦

Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 (Erlotinib or Tarceva) in combination with docetaxel

Book ID: 117659508
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 139 KB
Volume: 38
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(02)80816-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I, pharmacokinetic (PK) and biolog

Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin in patients with advanced solid malignancies

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 145 KB

A phase I dose escalation study of epide

A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors

✍ Karp, D.D; Ferrante, K.J; Tensfeldt, T.G; Thurer, R.L; LoCicero, J; Huberman, M. 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Phase I dose-finding and pharmacokinetic

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors

✍ Noboru Yamamoto; Atsushi Horiike; Yasuhito Fujisaka; Haruyasu Murakami; Tatsu Sh 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 367 KB

A phase I pharmacokinetic (PK) and seria

A phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (p) with advanced tumors known to overexpress the EGFR

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 256 KB